1. Home
  2. FSLR vs VTRS Comparison

FSLR vs VTRS Comparison

Compare FSLR & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Solar Inc.

FSLR

First Solar Inc.

N/A

Current Price

$171.23

Market Cap

22.0B

Sector

Technology

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$17.53

Market Cap

18.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSLR
VTRS
Founded
1999
1961
Country
United States
United States
Employees
N/A
30000
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.0B
18.7B
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
FSLR
VTRS
Price
$171.23
$17.53
Analyst Decision
Buy
Buy
Analyst Count
36
12
Target Price
★ $272.10
$19.40
AVG Volume (30 Days)
2.1M
★ 6.9M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
★ 2.71%
EPS Growth
★ 18.22
N/A
EPS
★ 7.14
0.05
Revenue
$5,219,376,000.00
★ $14,299,900,000.00
Revenue This Year
N/A
$3.42
Revenue Next Year
$17.30
$1.68
P/E Ratio
★ $24.87
$362.00
Revenue Growth
★ 24.09
N/A
52 Week Low
$170.80
$9.69
52 Week High
$320.95
$18.43

Technical Indicators

Market Signals
Indicator
FSLR
VTRS
Relative Strength Index (RSI) 33.78 61.05
Support Level $170.80 $15.94
Resistance Level $251.62 $18.23
Average True Range (ATR) 8.48 0.43
MACD -1.99 0.09
Stochastic Oscillator 2.86 67.56

Price Performance

Historical Comparison
FSLR
VTRS

About FSLR First Solar Inc.

First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: